LT3001 clinical trials
How each study uses LT3001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LT3001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Lumosa Therapeutics Co., Ltd. (5) · Shanghai Pharmaceuticals Holding Co., Ltd (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test LT3001.
- Dec 2026Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokePhase 2 · Shanghai Pharmaceuticals Holding Co., Ltd
- Dec 2026A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTPhase 2 · Lumosa Therapeutics Co., Ltd.
Studies
Open first, then newest update. How each study uses LT3001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS ParticipantRecruitingPhase 2Lumosa Therapeutics Co., Ltd.NCT07890298Written as LT3001 Drug Product
- A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic StrokeNot yet recruitingPhase 2Shanghai Pharmaceuticals Holding Co., LtdNCT07754825Written as LT3001 Drug:high dose
- Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokeRecruitingPhase 2Shanghai Pharmaceuticals Holding Co., LtdNCT05686642Written as LT3001 Drug:high dose
- A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTActive, not recruitingPhase 2Lumosa Therapeutics Co., Ltd.NCT05198323Written as LT3001 Drug Product
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy SubjectsCompletedPhase 1Lumosa Therapeutics Co., Ltd.NCT04809818Written as LT3001 drug product
- A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AISCompletedPhase 2Lumosa Therapeutics Co., Ltd.NCT04091945Written as LT3001 Drug Product
- A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS SubjectsCompletedPhase 2Lumosa Therapeutics Co., Ltd.NCT05403866Written as LT3001 Drug Product
What changed recently
From the registry's own updates since Oct 18, 2026.